Contrasting TBG Diagnostics (OTCMKTS:TDLAF) and Charlie’s (OTCMKTS:CHUCD)

TBG Diagnostics (OTCMKTS:TDLAFGet Free Report) and Charlie’s (OTCMKTS:CHUCDGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Earnings and Valuation

This table compares TBG Diagnostics and Charlie’s’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TBG Diagnostics $2.33 million 1.02 $530,000.00 N/A N/A
Charlie’s $16.69 million 1.77 -$7.19 million N/A N/A

TBG Diagnostics has higher earnings, but lower revenue than Charlie’s.

Analyst Recommendations

This is a summary of current recommendations and price targets for TBG Diagnostics and Charlie’s, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TBG Diagnostics 0 0 0 0 N/A
Charlie’s 0 0 0 0 N/A


This table compares TBG Diagnostics and Charlie’s’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TBG Diagnostics N/A N/A N/A
Charlie’s -140.60% N/A -327.67%

Risk & Volatility

TBG Diagnostics has a beta of -12.38, indicating that its share price is 1,338% less volatile than the S&P 500. Comparatively, Charlie’s has a beta of 5.57, indicating that its share price is 457% more volatile than the S&P 500.

Insider & Institutional Ownership

3.1% of Charlie’s shares are owned by institutional investors. 3.6% of TBG Diagnostics shares are owned by company insiders. Comparatively, 74.8% of Charlie’s shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Charlie’s beats TBG Diagnostics on 5 of the 8 factors compared between the two stocks.

About TBG Diagnostics

(Get Free Report)

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.

About Charlie’s

(Get Free Report)

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes e-cigarette liquids and vaping systems in the United States and internationally. The company also offers energy drink under the Bazi brand name. It sells its products through distributors, specialty retailers, and third-party online resellers to approximately 80 countries, primarily, including the United Kingdom, Italy, Spain, Belgium, Australia, Sweden, and Canada. The company was formerly known as True Drinks Holdings, Inc. and changed its name to Charlie's Holdings, Inc. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Receive News & Ratings for TBG Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TBG Diagnostics and related companies with's FREE daily email newsletter.